EPS for ESSA Pharma Inc. (EPI.TO) Expected At $-0.23

December 8, 2017 - By Stephen Andrade

 EPS for ESSA Pharma Inc. (EPI.TO) Expected At $ 0.23

Analysts expect ESSA Pharma Inc. (TSE:EPI.TO) to report $-0.23 EPS on December, 13.They anticipate $0.03 EPS change or 15.00 % from last quarter’s $-0.2 EPS. After having $-0.22 EPS previously, ESSA Pharma Inc.’s analysts see 4.55 % EPS growth. The stock increased 5.97% or $0.02 during the last trading session, reaching $0.355. About 45,800 shares traded. ESSA Pharma Inc. (TSE:EPI.TO) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. The company has market cap of $10.33 million. The Company’s product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.